Navigation Links
Amgen Announces 31 Percent Increase In 2013 First Quarter Dividend And Increase In Its Share Repurchase Authorization
Date:12/13/2012

nd uncertainties, including those discussed below and others that can be found in our Form 10-K for the year ended Dec. 31, 2011, and in our periodic reports on Form 10-Q and Form 8-K. Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. The Company's results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments (domestic or foreign) involving current and future products, sales growth of recently launched products, competition from other products (domestic or foreign) and difficulties or delays in manufacturing our products. In addition, sales of our products are affected by reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We, or others, could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
2. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
3. Amgen to Present at the Baird Growth Stock Conference
4. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
5. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
6. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
7. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
8. Amgen Completes Acquisition of KAI Pharmaceuticals
9. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
10. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
11. Amgen To Present At The Baird Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... , March 31, 2015 ... therapeutic market research report of 68 pages with ... business intelligence library. The report "Pemphigus - Pipeline ... the therapeutic development for Pemphigus , complete ... by drug target, mechanism of action (MoA), route ...
(Date:3/31/2015)... KENNEBUNK, Maine , March 31, 2015 /PRNewswire/ ... aggregated enrollment in Medicare Advantage (MA) plans in ... approximately 17.3 million people were enrolled in Medicare ... of more than 1.3 million members year-over-year.  54.3 ... the Centers for Medicare and Medicaid Services (CMS), ...
(Date:3/31/2015)... TUCSON, Ariz. , March 31, 2015  SynCardia ... Investigational Device Exemption (IDE) clinical study on the effective ... The ... with as many as 30 heart failure patients. Patients ... Total Artificial Heart as a bridge to a donor ...
Breaking Medicine Technology:Pemphigus Therapeutic Development and Pipeline Review H1 2015 2Pemphigus Therapeutic Development and Pipeline Review H1 2015 3Pemphigus Therapeutic Development and Pipeline Review H1 2015 4Medicare Advantage Enrollment Reaches 17 Million According to Mark Farrah Associates 2FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 2FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 3FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 4
... BRIGHTON, Mich., March 15, 2012 LifeSecure Insurance ... one-stop online shop where caregivers can access quality home ... needs of loved ones. LifeSecure,s Caregiver,s ... daily living aids and home modification tools to medical ...
... 15, 2012 Heptares Therapeutics, the leading GPCR ... Kenny, will present overview of the Company at 09:45am CET ... Annual BIO-Europe Spring international partnering conference. The presentation will take ... which is produced by EBD Group, is taking place at ...
Cached Medicine Technology:LifeSecure Opens Online Caregiver's Marketplace 2Heptares to Present at 6th Annual BIO-Europe Spring Conference on 20 March 2012 2
(Date:4/1/2015)... Natural fertility experts from around the world will ... Integrative Fertility Symposium ( https://ifsymposium.com/ ) April 30th to ... 515 West Hastings Street, Vancouver BC. There will also ... pm to 5:00 pm at Harbour Centre. , "The ... in the world to bring together reproductive endocrinologists, urologists, ...
(Date:4/1/2015)... Raleigh, NC (PRWEB) April 01, 2015 ... treatment option available to them, thanks to the FDA’s ... here to read the full story on the ... vaccine made from a modified version of the bacteria ... agreed to give its manufacturer grant funding and other ...
(Date:4/1/2015)... CA (PRWEB) April 01, 2015 Eighty ... in athletics grants from California Casualty . Many ... or reduced-cost lunches and subsequently have fewer and fewer ... named after California Casualty Chairman Emeritus Thomas R. Brown, ... translated to the classroom. Since its inception in ...
(Date:4/1/2015)... North Carolina (PRWEB) April 01, 2015 ... and assisted living placement counseling, recently opened a new office ... Amada franchise partners Tracy and Lee Bissett decided to make ... rights to the area after over 20 years of experience ... on Thursday, April 2nd. , When asked what ...
(Date:4/1/2015)... On April 1st, 2015, Dr. Jason Helfrich, co-founder of 100% ... discuss the epidemic known as “Text Neck.” The average human head ... which it is bent forward, such as when bent to look ... cause poor posture often times leading to wear and tear of ... on their cell phone device emailing, keeping up with social media ...
Breaking Medicine News(10 mins):Health News:Vancouver Hosts the World's First Integrative Fertility Symposium 2Health News:Vancouver Hosts the World's First Integrative Fertility Symposium 3Health News:Orphan Drug Approval May Mean New Treatment Option for Mesothelioma, According to Surviving Mesothelioma 2Health News:California Casualty Teams Up With 87 High Schools, Awarding Over $100,000 in 2015 Thomas R. Brown Athletics Grants 2Health News:California Casualty Teams Up With 87 High Schools, Awarding Over $100,000 in 2015 Thomas R. Brown Athletics Grants 3Health News:California Casualty Teams Up With 87 High Schools, Awarding Over $100,000 in 2015 Thomas R. Brown Athletics Grants 4Health News:California Casualty Teams Up With 87 High Schools, Awarding Over $100,000 in 2015 Thomas R. Brown Athletics Grants 5Health News:Amada Senior Care Expands to Eastern North Carolina 2Health News:Dr. Jason Helfrich, Co-Founder of 100% Chiropractic, is a Guest on Better TV to Discuss “Text Neck” 2
... one day lead to new targets, treatments, researcher says , ... have spotted two new regions of the human genome that ... The findings, published in the June issue of the ... patients or people at risk for the devastating dementia just ...
... 2010 Researchers at the Translational Genomics Research Institute ... Virginia G. Piper Cancer Center at Scottsdale Healthcare have ... of patients with an aggressive type of lung cancer. ... which patients with small cell lung cancer are resistant ...
... CA (June 14, 2010) Apple juice can be a useful ... the normal progression of moderate-to-severe Alzheimer,s Disease (AD), according to ... Other Dementias (AJADD), published by SAGE. In the ... of apple juice a day for a month, their caregivers ...
... HOUSTON - Margaret M. Fields, an advanced practice nurse ... Department of Gynecologic Oncology, is the recipient of the ... by The Brown Foundation, Inc. A committee of ... staff reviewed nominations from peers and patients before selecting ...
... ... on popular osteoporosis drugs discontinue their treatment within 6 months. Amgen’s Prolia is the newest ... every 6 months via injection. , ... (Vocus) June 14, 2010 -- According to a recent analysis by SDI , ...
... describes the current state of the science in combating ... In his article in the June 10, 2010 ... Neuroblastoma," Maris reviews the field,s latest research knowledgemuch of ... at The Children,s Hospital of Philadelphia. Maris directs a ...
Cached Medicine News:Health News:Scientists Spot More Genes Related to Alzheimer's 2Health News:TGen-VARI-SHC research helps predict success with cancer drugs 2Health News:TGen-VARI-SHC research helps predict success with cancer drugs 3Health News:Peg Fields to receive MD Anderson's highest nurse-oncologist honor 2Health News:Peg Fields to receive MD Anderson's highest nurse-oncologist honor 3Health News:SDI Reports: Roughly Half of Patients Prescribed the Most Popular Osteoporosis Drugs Discontinue Therapy Within 6 Months -- Amgen's Prolia Offers New Dosing Option 2Health News:Internationally known neuroblastoma expert reviews progress versus challenging childhood cancer 2
... trocar has a sharp linear blade and a ... VERSAPORT™ PLUS V2 trocar is available in 5 ... 5 mm-12 mm long sizes with a radiolucent ... has a sharp linear blade and a spring-loaded ...
The Auto Suture™ Woodford Spike™ Trocar and Cannula is a sterile, single-use device designed for primary punctures during laparoscopy. Dexide refers to a separate offering of trocars from...
... of Surgical Access ...unlike any trocar system ... system is actually four systems in one ... and clinically adaptive to all of your ... and bladed or dilating tip styles, OnePort™ ...
Mini-Finesse 5mm Dilating Trocar, hook electrode, two lengths, mini or basic kit....
Medicine Products: